Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Curr Opin Pharmacol. 2012 Apr;12(2):147-54. doi: 10.1016/j.coph.2012.01.003. Epub 2012 Jan 25.
Percutaneous coronary intervention (PCI) with bare-metal stents (BMS) has been performed increasingly ever since its introduction in the late 1970s. BMS have been replaced by drug-eluting stents (DES), and many interventional cardiologists consider this as a breakthrough therapy that might compete with coronary artery bypass grafting (CABG) as the standard treatment for coronary artery disease. Several DES are currently used and elute different agents. This review described what these agents are and provides an overview regarding the outcomes and associated adverse events. More importantly, this review compares outcomes of PCI with DES to CABG for patients with left anterior descending coronary artery involvement, left main involvement, or multivessel disease.
经皮冠状动脉介入治疗(PCI)联合裸金属支架(BMS)自 20 世纪 70 年代末问世以来应用日益广泛。BMS 已被药物洗脱支架(DES)取代,许多介入心脏病学家认为这是一种突破性疗法,可能与冠状动脉旁路移植术(CABG)竞争成为冠心病的标准治疗方法。目前有几种 DES 正在使用,洗脱不同的药物。本文描述了这些药物是什么,并概述了其结果和相关不良事件。更重要的是,本文比较了 PCI 联合 DES 与 CABG 治疗左前降支病变、左主干病变或多支血管病变患者的结果。